CN112996501A - 癌症中紫杉类纳米乳剂与免疫疗法的联合 - Google Patents

癌症中紫杉类纳米乳剂与免疫疗法的联合 Download PDF

Info

Publication number
CN112996501A
CN112996501A CN201880092498.5A CN201880092498A CN112996501A CN 112996501 A CN112996501 A CN 112996501A CN 201880092498 A CN201880092498 A CN 201880092498A CN 112996501 A CN112996501 A CN 112996501A
Authority
CN
China
Prior art keywords
sbt
oil
cancer
tumor
dha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880092498.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·E·伊根
M·安米吉
I·小岛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targagenix Inc
Research Foundation of the State University of New York
Original Assignee
Targagenix Inc
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targagenix Inc, Research Foundation of the State University of New York filed Critical Targagenix Inc
Publication of CN112996501A publication Critical patent/CN112996501A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880092498.5A 2017-12-20 2018-12-19 癌症中紫杉类纳米乳剂与免疫疗法的联合 Pending CN112996501A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762608015P 2017-12-20 2017-12-20
US62/608,015 2017-12-20
PCT/US2018/066465 WO2019126302A2 (en) 2017-12-20 2018-12-19 Combination taxoid nanoemulsion with immunotherapy in cancer

Publications (1)

Publication Number Publication Date
CN112996501A true CN112996501A (zh) 2021-06-18

Family

ID=66815378

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880092498.5A Pending CN112996501A (zh) 2017-12-20 2018-12-19 癌症中紫杉类纳米乳剂与免疫疗法的联合

Country Status (6)

Country Link
US (2) US11497713B2 (enExample)
EP (1) EP3752130A4 (enExample)
JP (2) JP7450888B2 (enExample)
CN (1) CN112996501A (enExample)
CA (1) CA3121615A1 (enExample)
WO (1) WO2019126302A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116173094A (zh) * 2023-03-15 2023-05-30 中南大学湘雅二医院 一种杜仲籽油在制备抗癌药物中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7518604B2 (ja) * 2016-06-07 2024-07-18 タルガジェニックス，インコーポレイテッド タキソイド薬物のナノエマルション組成物、並びに標的癌細胞及び癌幹細胞に対するその使用方法
CA3121615A1 (en) * 2017-12-20 2019-06-27 Targagenix, Inc. Combination taxoid nanoemulsion with immunotherapy in cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2255637A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Conjugates of cis-docosahexaenoic acid and paclitaxel
US20170112800A1 (en) * 2014-04-03 2017-04-27 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
WO2017214260A1 (en) * 2016-06-07 2017-12-14 Targagenix, Inc. Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544128A1 (en) 2003-10-30 2005-05-12 The Research Foundation Of State University Of New York Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
JP6042527B2 (ja) * 2012-04-04 2016-12-14 ハロザイム インコーポレイテッド 抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療
CA3121615A1 (en) * 2017-12-20 2019-06-27 Targagenix, Inc. Combination taxoid nanoemulsion with immunotherapy in cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2255637A1 (en) * 1996-05-22 1997-11-27 Neuromedica, Inc. Conjugates of cis-docosahexaenoic acid and paclitaxel
US20170112800A1 (en) * 2014-04-03 2017-04-27 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
WO2017214260A1 (en) * 2016-06-07 2017-12-14 Targagenix, Inc. Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GULZAR AHMAD等: "Nanoemulsion Formulation of a Novel Taxoid DHA-SBT-1214 Inhibits Prostate Cancer Stem Cell-Induced Tumor Growth", CANCER LETT, vol. 406, pages 71 - 80, XP085165371, DOI: 10.1016/j.canlet.2017.08.004 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116173094A (zh) * 2023-03-15 2023-05-30 中南大学湘雅二医院 一种杜仲籽油在制备抗癌药物中的应用

Also Published As

Publication number Publication date
JP7450888B2 (ja) 2024-03-18
US20190183796A1 (en) 2019-06-20
US12186428B2 (en) 2025-01-07
JP2021517906A (ja) 2021-07-29
JP2024023463A (ja) 2024-02-21
WO2019126302A2 (en) 2019-06-27
WO2019126302A3 (en) 2020-03-26
US20230082272A1 (en) 2023-03-16
EP3752130A2 (en) 2020-12-23
CA3121615A1 (en) 2019-06-27
US11497713B2 (en) 2022-11-15
EP3752130A4 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
Guimarães et al. Nanoparticles for immune cytokine TRAIL-based cancer therapy
Valcourt et al. Nanoparticle-mediated co-delivery of Notch-1 antibodies and ABT-737 as a potent treatment strategy for triple-negative breast cancer
US12186428B2 (en) Combination taxoid nanoemulsion with immunotherapy in cancer
El-Readi et al. Cancer nanomedicine: a new era of successful targeted therapy
Nesbitt et al. Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer
Boone et al. Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy
Gilabert-Oriol et al. Liposomal formulations to modulate the tumour microenvironment and antitumour immune response
Jiang et al. Peptide-targeted high-density lipoprotein nanoparticles for combinatorial treatment against metastatic breast cancer
Raikwar et al. Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape
Tiwari et al. Kajal; Salvi, P.; Singh, SK; Gautam, V
Trinh et al. Silica-based nanomaterials as drug delivery tools for skin cancer (melanoma) treatment
Shetab Boushehri et al. A nanoparticle-based approach to improve the outcome of cancer active immunotherapy with lipopolysaccharides
Ahmad et al. DHA-SBT-1214 taxoid nanoemulsion and anti–PD-L1 antibody combination therapy enhances antitumor efficacy in a syngeneic pancreatic adenocarcinoma model
JP2019523226A (ja) タキソイド薬物のナノエマルション組成物、並びに標的癌細胞及び癌幹細胞に対するその使用方法
Janicka et al. Use of nanotechnology for improved pharmacokinetics and activity of immunogenic cell death inducers used in cancer chemotherapy
Zhang et al. Chemoimmunological cascade cancer therapy using fluorine assembly nanomedicine
ES2984148T3 (es) Medicamento de combinación que contiene una composición liposómica que encapsula un fármaco y un inhibidor de punto de control inmunitario
JP2022116289A (ja) ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
Kanp et al. Exploring the Potential of Nanocarriers for Cancer Immunotherapy: Insights into Mechanism, Nanocarriers, and Regulatory Perspectives
Nadukkandy et al. Tracing new landscapes in the arena of nanoparticle-based cancer immunotherapy
Lúcio et al. Functional lipid nanosystems in cancer
Khezrian et al. A review of recent advances in peptide-based anticancer therapeutic vaccines and nanovaccines in prostate cancer
US20230285295A1 (en) Combined pharmaceutical formulation comprising gemcitabine-containing liposome composition and immune checkpoint inhibitor
Abdelgalil et al. Engineered nanomedicines for augmenting the efficacy of colorectal cancer immunotherapy
Cremolini et al. Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. Nanomaterials 2021, 11, 661

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination